Quoin Pharmaceuticals Ltd.
QNRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$4.01
KIRA · Stoqly’s AI analyst, in plain words
- Quoin Pharmaceuticals Ltd. lost $15.8M in fiscal 2025.
Market cap
—
P/E
—
Revenue
—
Net income
−$15.8M
Free cash flow
—
Operating margin
—
Quoin Pharmaceuticals Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$15.8M
No. It lost money last year.
What Quoin Pharmaceuticals Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Quoin Pharmaceuticals Ltd.
- CIK
- 0001671502
Quoin Pharmaceuticals Ltd. · QNRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$21.5M | −$9.4M | −$8.7M | −$9.0M | −$15.8M |
| Cash | |||||
| Cash from operations | −$5.7M | −$8.5M | −$7.9M | −$7.9M | −$13.5M |
| Debt and strength | |||||
| Cash and short-term investments | $7.5M | $2.9M | $2.4M | $14.1M | $18.7M |
| Shareholders' equity | $0.7M | $7.4M | $5.7M | $9.2M | $13.1M |
| Current ratio | 1.8x | 3.8x | 3.2x | 3.6x | 3.6x |
| Returns and quality | |||||
| Return on equity | −3,266.8% | −232.7% | −132.9% | −120.6% | −141.6% |
| Return on tangible equity | — | −141.0% | −171.0% | −102.8% | −124.1% |
Insiders bought, 12 months
$0.3M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Quoin Pharmaceuticals Ltd. · QNRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.01 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001671502). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.